# Phase 2 stomach cancer trials recruiting: 149 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 149 trials in phase 2 for stomach cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 stomach cancer trials: 149 rows for $7.45, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/stomach-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 149
- Recruiting or not yet: 149
- Read on: November 19, 2026

## Trials

The 25 newest of 149, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 17, 2026 | NCT07943533 | HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | HER2-Positive, Limited Metastatic, Gastric Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07943533) |
| November 16, 2026 | NCT07938021 | HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis), Gastroesophageal Junction Cancer, Biliary Tract Cancer (BTC) | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938021) |
| November 12, 2026 | NCT07933471 | Total Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Beijing Tsinghua Chang Gung Hospital | Phase 2 | Recruiting | Gastric Cancer (GC), Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933471) |
| November 5, 2026 | NCT07920224 | Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | Stomach Neoplasms | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920224) |
| November 3, 2026 | NCT07913165 | A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Gastric Cancer (GC) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913165) |
| November 3, 2026 | NCT07912606 | D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912606) |
| November 2, 2026 | NCT07911280 | A Phase II, Trial of Neoadjuvant Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy | Samsung Medical Center | Phase 2 | Recruiting | Gastric Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911280) |
| October 29, 2026 | NCT07904442 | Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis | Anhui Provincial Cancer Hospital | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904442) |
| October 29, 2026 | NCT07902648 | Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction... | Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902648) |
| October 14, 2026 | NCT07874425 | Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC | Fudan University | Phase 2 | Not yet recruiting | Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874425) |
| October 14, 2026 | NCT07872722 | Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction... | National Cancer Center, Japan | Phase 2 | Recruiting | CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872722) |
| October 14, 2026 | NCT07872696 | Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Not yet recruiting | Gastric Neoplasms | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872696) |
| September 14, 2026 | NCT07819019 | A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Phase 2 | Not yet recruiting | Stomach Neoplasms, Gastric Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819019) |
| August 31, 2026 | NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | University of California, Irvine | Phase 2 | Recruiting | Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795749) |
| August 18, 2026 | NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770100) |
| July 17, 2026 | NCT07709767 | Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma | Tang-Du Hospital | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709767) |
| July 14, 2026 | NCT07702292 | \[68Ga\]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | Blue Earth Diagnostics | Phase 2 | Recruiting | Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer (GC), Pancreatic Ductal Adenocarcinoma (PDAC), Invasive... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702292) |
| July 9, 2026 | NCT07692334 | Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma | West China Second University Hospital | Phase 2 | Not yet recruiting | Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Becotatug Vedotin, Pucotenlimab | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692334) |
| July 9, 2026 | NCT07692204 | A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer | Sanofi | Phase 2 | Recruiting | Gastric Cancer, Oesophageal Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692204) |
| July 8, 2026 | NCT07689851 | Chemoradiotherapy and SHR-1701 in Patients With Unresectable Gastric Cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689851) |
| July 6, 2026 | NCT07685704 | Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685704) |
| June 25, 2026 | NCT07669740 | A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Not yet recruiting | Gastric Cancer (Diagnosis) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669740) |
| June 22, 2026 | NCT07658872 | Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | Sichuan University | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658872) |
| June 18, 2026 | NCT07655661 | Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer. | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655661) |
| June 17, 2026 | NCT07655024 | TAIC FOLFOX for Locally Advanced G/GEJA | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Phase 2 | Recruiting | Gastric Cancer (Diagnosis), Gastroesophageal Junction Adenocarcinoma | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655024) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| The First Affiliated Hospital with Nanjing Medical University | 11 |
| Fudan University | 9 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 6 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 4 |
| University of California, Irvine | 3 |
| Ruijin Hospital | 3 |
| Nanfang Hospital, Southern Medical University | 3 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 3 |
| Sichuan University | 3 |
| Shandong Tumor Hospital | 2 |
| Shanghai Zhongshan Hospital | 2 |
| Chinese PLA General Hospital | 2 |
| Tianjin Medical University Cancer Institute and Hospital | 2 |
| Convalife (Shanghai) Co., Ltd. | 2 |
| Qilu Hospital of Shandong University | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Nizhny Novgorod Regional Clinical Oncology Center | 2 |
| China Medical University, China | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| Peking University | 1 |
| University of Illinois Chicago | 1 |
| Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | 1 |
| Toray Industries, Inc | 1 |
| Anhui Provincial Cancer Hospital | 1 |
| Asan Medical Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 84 |
| United States | 24 |
| South Korea | 11 |
| Japan | 9 |
| Spain | 9 |
| United Kingdom | 8 |
| Italy | 7 |
| France | 7 |
| Canada | 6 |
| Taiwan | 6 |
| Australia | 5 |
| Netherlands | 4 |
| Germany | 4 |
| Poland | 3 |
| Singapore | 3 |
| Georgia | 3 |
| Norway | 2 |
| Russia | 2 |
| Switzerland | 2 |
| Turkey (Türkiye) | 2 |
| Hungary | 2 |
| Denmark | 2 |
| Israel | 1 |
| Brazil | 1 |
| Belgium | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
- [Wills, trusts and probate law firms in the United States](https://specstream.ai/data/businesses/wills-trusts-and-probate-law-firms/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [Hospitals in the United States](https://specstream.ai/data/businesses/hospitals/united-states)
- [Natural gas utilities in the United States](https://specstream.ai/data/businesses/natural-gas-utilities/united-states)
